Emmaus Life Sciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

SELECTED FINANCIAL STATEMENT CAPTIONS - LIABILITIES (Tables)

3 Months Ended

Mar. 31, 2023

Accounts payable and accrued expenses consisted of the following at March 31, 2023 and December 31, 2022 (in thousands):


	March 31, 2023		December 31, 2022
Accounts payable:
Clinical and regulatory expenses	$	393	$	361
Professional fees		652		626
Selling expenses		1,756		1,363
Manufacturing costs		1,023		650
Non-employee board member compensation		552		484
Other vendors		357		301
Total accounts payable		4,733		3,785
Accrued interest payable, related parties		377		144
Accrued interest payable		2,595		2,381
Accrued expenses:
Payroll expenses		1,241		1,263
Government rebates and other rebates		4,973		5,536
Other accrued expenses		504		440
Total accrued expenses		6,718		7,239
Total accounts payable and accrued expenses	$	14,423		13,549

Other current liabilities consisted of the following at March 31, 2023 and December 31, 2022 (in thousands):


	March 31, 2023		December 31, 2022
Trade discount	$	2,500	$	1,200
Unearned revenue (a)		10,000		10,000
Other current liabilities		1,472		1,717
Total other current liabilities	$	13,972	$	12,917

(a) The amount represents upfront fee received from Telcon pursuant to the distributor agreement. Refer Note 3 for additional details.

Other long-term liabilities consisted of the following at March 31, 2023 and December 31, 2022 (in thousands):


	March 31, 2023		December 31, 2022
Trade discount	$	20,223	$	21,682
Other long-term liabilities		33		32
Total other long-term liabilities	$	20,256	$	21,714